NCT04265950

Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial

Name: Clinical Trial NCT04265950
Creator: Fred Hutchinson Cancer Research Center
Keywords: HIV Infection, Recombinant Human Papillomavirus Nonavalent Vaccine, Phase 4, biological, clinical trial, Brazil,Peru

Multicenter, Randomized, Open-Label Trial in Children and Adolescents to Establish Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV

Fred Hutchinson Cancer Research Center·Phase 4·ClinicalTrials.gov·biologicalRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: HIV Infection
Drug/Device/Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Study type: Interventional
Intervention type: biological

Sponsor & location

Primary sponsor: Fred Hutchinson Cancer Research Center
Location: Rio de Janeiro,Lima, Brazil,Peru

Timeline & enrollment

Phase: Phase 4
Start date: Mar 10, 2022
End date: Jun 30, 2026
Enrollment: 100 participants

Primary outcome

Human papillomavirus type 16 (HPV16) neutralizing antibody geometric mean titers (GMTs) (Arm 1 versus [vs.] Arm 2)

Summary

This phase IV trial compares 3 different dosing schedules to find the optimal number of doses for HPV vaccination in children and adolescents living with HIV. Comparing 3 different dosing schedules may help researchers determine whether a single dose of HPV vaccine could be effective in preventing HPV in children and adolescents living with HIV.

ICD-10 classifications

HIV disease resulting in other viral infectionsHuman immunodeficiency virus [HIV] diseaseHIV disease resulting in other bacterial infectionsAcute HIV infection syndromeUnspecified human immunodeficiency virus [HIV] disease

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT04265950
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT04265950 through Pure Global AI's free database. This Phase 4 trial is sponsored by Fred Hutchinson Cancer Research Center and is currently Recruiting. The study focuses on HIV Infection. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.